INCHEON, South Korea--(BUSINESS WIRE)--Celltrion Healthcare today announced that the European Commission (EC) has granted marketing authorisation for Remsima (infliximab, CT-P13) subcutaneous (SC) formulation for the treatment of adult patients with ankylosing spondylitis, Crohns disease, ulcerative colitis, psoriatic arthritis and psoriasis.1

The approval follows a positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) in June and is based on data from a pivotal study comparing the pharmacokinetics, efficacy and safety of the SC and intravenous (IV) formulations of Remsima in people with active Crohns disease and ulcerative colitis, throughout a 1-year treatment period.2,3 Based on the results of the pivotal study, a 120 mg fixed dose of Remsima SC has been approved for use in the European Union (EU), in adults regardless of body weight, in both existing and newly added indications.

Professor Stefan Schreiber, Director of the Clinic for Internal Medicine at Kiel Campus of the University Hospital Schleswig-Holstein in Germany said: The subcutaneous formulation of Remsima (Remsima SC) has been shown to have very high efficacy, and favourable data, which are fully comparable to the efficacy and safety profile of the IV formulation. Todays approval marks an important progress for the gastroenterology community as it means that treatment can now be administered in significantly less time, thereby providing patients more flexibility and control over how they receive their treatment.

We are pleased to announce this important regulatory milestone earlier than we expected, with the European Commission prioritising review of this important new administration option. We will accelerate the launch process on a country-by-country basis in order to expand treatment options for patients with chronic inflammatory diseases such as inflammatory bowel disease and ankylosing spondylitis, said Hyoung-Ki Kim, Vice Chairman at Celltrion Healthcare. We will do our best to make Remsima SC available as early as possible and hope this medication will contribute to minimising the risks involved with administering medical treatments during the COVID-19 pandemic.

Celltrion anticipates receiving approval of Remsima SC in 97 countries, including 31 countries in Europe.

-- ENDS --

Notes to Editors:

About Remsima (CT-P13) intravenous (IV) formulation1Remsima IV is usually given as 3 mg per kg/body weight in rheumatoid arthritis (RA) and as 5 mg per kg/body weight for the other indications. Infliximab IV is given as an infusion over two hours. All patients are monitored for any reactions during the infusion and for at least one to two hours afterwards.

About Remsima CT-P13 subcutaneous (SC) formulation4,5A 120 mg fixed dose of Remsima SC has been granted marketing authorisation in the EU, in adults regardless of body weight, in all previously approved indications for the IV formulation. Remsima SC has three administration options; via a pre-filled pen (auto injector), pre-filled syringe or pre-filled syringe with needle safeguard. The SC formulation has the potential to enhance treatment options for the use of infliximab biosimilar by providing high consistency in drug exposure and a convenient method of administration.

About CT-P13 (biosimilar infliximab)CT-P13 is developed and manufactured by Celltrion, Inc. and was the worlds first monoclonal antibody biosimilar approved by the European Commission (EC). It is indicated for the treatment of eight autoimmune diseases including RA and IBD. It was approved by the EC under the trade name Remsima in September 2013 and launched in major EU countries in early 2015. The US FDA approved CT-P13 in April 2016 under the trade name Inflectra. CT-P13 is approved in more than 94 countries (as of July 2020) including the US, Canada, Japan and throughout Europe.

About Celltrion HealthcareCelltrion Healthcare is committed to delivering innovative and affordable medications to promote patients access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries. For more information please visit: https://www.celltrionhealthcare.com/en-us

Forward-looking statement disclaimerCertain information set forth in this press release contains statements related to our future business and financial performance, and future events or developments involving Celltrion Healthcare, that may constitute forward-looking statements, under pertinent securities laws.

These statements may be identified by words such as will, has potential to, brings, if approved, would, could, opportunity, hope, is considering the negative of these words or such other variations thereon or comparable terminology.

In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion Healthcare's management, of which many are beyond its control.

Forward-looking statements are provided to allow potential investors the opportunity to understand managements beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.

Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this presentation are based upon what management of Celltrion Healthcare believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Celltrion Healthcare undertakes no obligation to update forward-looking statements if circumstances or managements estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

References

1 European Medicines Agency Summary of Product Characteristics (SmPC). Remsima.

2 Reinisch W, et al. A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 1-year result from a Phase 1 open-label randomised controlled trial in patients with active Crohns disease. European Crohns and Colitis Organisation 2019. Abstract no: A-1103.

3 Ben-Horin S, et al. A novel subcutaneous infliximab (CT-P13): 1-year results including switching results from intravenous infliximab (CT-P13) in patients with active Crohns disease and ulcerative colitis. Oral presentation (OP24). Presented at ECCO 2020.

4 Yoo DH, Jaworski J, Matyska-Piekarska E et al. A Novel Formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: One-year results from part one of a Phase I/III randomised controlled trial in patients with rheumatoid arthritis. Poster (FRI0128). Presented at EULAR 2019.

5 Westhovens R, Wiland P, Zawadzki M et al. A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 30-week results from part two of a Phase I/III randomised controlled trial in patients with rheumatoid arthritis. Poster (SAT0170). Presented at EULAR 2019.

More here:

European Commission grants marketing authorisation for world's first subcutaneous formulation of infliximab, Remsima SC, for an additional five...

The year 2020 began with a not-so-great scenario that escalated rapidly into a pandemic that has crippled the functioning of the world. A lot has happened over the course of these past 4 months with a large number of people losing their lives to a microscopic virus. Coronavirus and COVID-19 are words that are familiar to every person in the world since it has made a huge impact on everything that rules peoples hectic lives; Business, economy and simply put, their way of living. The novelty of the virus is a research field in itself with scientists looking into its morphology and genetic structure, discovering new facts about this unknown microorganism. With most of the people who got affected being asymptomatic, scientists also have to work faster to detect the properties of this virus and easier ways to detect it to increase the number of people being tested per day. Therefore, it is a need of the hour for those susceptible to have a vaccine they can rely on that will be effective in helping them develop immunity against this virus. With the rush to develop a vaccine, many countries have applied for their drug compounds to be used for phase 3 or phase 4 trials. COVAX, an initiative by Gavi, a public-private partnership, to support the acceleration of the designing, development, and distribution of vaccines. With countries around the world trying to find a vaccine, about 130 vaccines are under testing in various phases. India is also actively taking part in this vaccine rush and has 2 possible drugs in different trial stages; Covaxin by Bharat Biotech and ZyCov-D by Zydus which are proving to be hopeful. Along with these two, Biocon, a global biopharma company based in Bangalore, recently announced that they have received a green flag from the Drug Controller General of India to release their novel biologic, Itolizumab (ALZUMAb) into the market for restricted emergency use in treating COVID-19 patients with moderate to severe complications.

But why is Itolizumab, a drug used in treating a chronic skin disease like psoriasis, being used to treat patients affected with COVID-19?

The SARS-CoV-2 virus affects individuals by triggering the immune system to generate a large number of cytokines which can attack the organs like lungs, etc. and can lead to multiple organ failure or death. Here is where Itolizumab seems to help the affected individuals.

Kiran Mazumder-Shaw, the Executive Chairperson of Biocon, said in a press release that this novel drug has been approved by the regulator, based on the promising data obtained from a pivotal two-arm, randomized trial involving 30 eligible patients across New Delhi and Mumbai. Out of these 30 patients, 20 were administered with Itolizumab with the best care, making them the test arm and the remaining 10 were not administered Itolizumab, making them the control arm. After a period of one month, the mortality rates were observed. The results were promising, as all 20 of the test arm patients experienced a full recovery. 3 patients out of the 10 in the control arm died.

Itolizumab proved itself to be efficient by meeting the key efficacy parameter of improving lung function without a hike oxygen flow as required by the patients in the control arm and also displayed suppression or reduction in the expression of clinical markers of inflammation. It has also worked tremendously in controlling moderate to severe ARDS (Acute Respiratory Distress Syndrome) induced by COVID-19 and has shown its efficacy in treating elder patients too. This clinical trial proved to be helpful in giving emergency treatment options to patients to reduce complications. Itolizumab, the psoriasis drug turned COVID-19 treatment, is shown to work best if administered before the cytokine release begins and helps to prevent the cytokine storm from intensifying.

This drug can be the best bet since it already is available in the market for the treatment of psoriasis, implying the fact that it is safe for human usage which has been proven by the 4 phase trials that were conducted before its release in 2013 by Biocon. Itolizumab acts by binding to the CD6 receptor and modulating it to prevent the T-lymphocyte activation thereby reducing the cytokine storm that turns into a deadly immune response.

Biocon is very well known for its unique biologics and pharmaceutical products in India and has a lot of global connections, Equillium being one of them. Equillium, a biotechnology company is planning to initiate a global study of this novel drug, Itolizumab, to make sure a large number of people get benefitted within a short period. Equillium is partnering with Biocon for Itolizumab in U.S., Canada, Australia, and New Zealand.

Bruce Steel, the co-founder, and CEO of Equillium said that they are working with Biocon to assess the further processes involved in accelerating the use of Itolizumab to treat COVID-19 patients in the U.S and abroad. The drug is being evaluated at present under two INDs for treating acute graft-vs-host disease and lupus nephritis, plus a clinical study in uncontrolled asthma in Australia and New Zealand.

Similarly, Itolizumab has been used to treat COVID-19 patients in Cuba too. The reports from Cuba were similar to the one obtained in the trial done in India and it shows a very low mortality rate in the patients who were administered with Itolizumab. The dosage being administered is a 25mg/5ml formulation at the rate of 4 vials per patient. Each vial costs Rs. 7,950. Therefore, the total dosage costs around Rs. 35,000.

The success and approval of Itolizumab show us that we can still hope for a better tomorrow with many individuals carrying out endless research works to find a solution. The efforts are enormous and we can only hope for them to be fruitful. With vaccines under trial and testing, the best we, as general citizens, can do is to stay calm and help others do the same. It is our responsibility to take enough care of our health and in this case, the health of our loved ones too.

Like Loading...

Related

Go here to see the original:

Psoriasis Drug Being Used To Treat COVID-19; Why Itolizumab? - Inventiva

This article was originally published here

J Dermatolog Treat. 2020 Jul 24:1-14. doi: 10.1080/09546634.2020.1800578. Online ahead of print.

ABSTRACT

Background. The beginning of 2020 has been marked by COVID-19 pandemic, with a strong impact on several national health systems worldwide.Objective. To describe the impact of COVID-19 pandemic in a cohort of Italian psoriatic patients treated with biologics.Methods. A telephone survey was conducted in May 4-10, 2020 about the Italian lockdown period (March 09th May 03rd 2020) in a cohort of psoriatic patients treated with biologics, asking about any exposure to COVID-19, disease status, continuation of therapy, work activity and psychological status through Hospital Anxiety and Depression Scale (HADS), Perceived Stress Scale (PSS) and Brief Resilience Scale (BRS).Results. 226 patients were interviewed, with no COVID-19 positive cases. Sixty-three of 226 (27.9%) described worsening of the disease with a correlation to drug withdrawal [43/226 (19%)]. Correlation was also found between the worsening of psoriasis and HADS anxiety, HADS depression, BRS and PSS abnormal scores considered both as categorical and continuous variables. No correlation was found between worsening of psoriasis and work activity.Conclusion. Uncertainty about whether biologics could increase the risk of SARS-CoV-2 infection led to drug withdrawal with subsequent worsening of psoriasis. Moreover, psychological status also had a direct influence on the clinical course of the disease.

PMID:32705945 | DOI:10.1080/09546634.2020.1800578

See the rest here:

The impact of COVID-19 pandemic in a cohort of Italian psoriatic patients treated with biological therapies - DocWire News

Shutterstock.com

By C. Moon Reed (contact)

Saturday, July 25, 2020 | 2 a.m.

Skin. Its our bodys biggest organ. Our protective envelope exists to keep the outside world out and the inside in. And yet its easy to ignore, up until the moment something goes wrong. Whats that weird rash? Who knows? Sure, you can use a phone filter to make your skin look great, but its better to address the problem and enjoy clear skin.

Weve rounded up info on some of the most common skin conditions that affect mankind, but this shouldnt replace professional medical advice. If you think something looks wrong, please consult a doctor.

Prevention is the best cure, so follow these simple steps to keep your skin healthy and happy.

Wash your hands.

Practice good hygiene.

Manage stress.

Eat a healthy diet.

Sleep enough.

Moisturize to prevent dry, cracked skin.

Dont share personal items like towels, razors and nail clippers.

Avoid touching your face.

Dont pick at, shave over, pop or scratch irritated skin, no matter how tempting.

Dont touch other peoples skin lesions.

Cover skin wounds, warts, etc. to speed healing and prevent cross-contamination.

Wear flip-flops around swimming pools and public showers.

Protect yourself from sun damage.

ACNE

Its the bane of pubescence. But pimples can linger beyond the teenage years.

Who: Everybody. Its the most common skin issue in the United States.

Cause: Pores clogged by dead skin cells get infected by a common skin bacteria, P. acnes. Risk factors include genetics, hormones, being female.

Symptoms: From cysts to blackheads to pustules and whiteheads, these blemishes can plague the face, chest, back, arms and buttocksand lead to scarring and dark spots.

Contagious? No.

Treatment: Start with over-the-counter topical treatments and see a dermatologist for prescription treatment if your acne is severe or not responding to other efforts. Do not pop pimples; it can make them worse and cause scarring.

CONTACT DERMATITIS

A general term for the type of rash one gets when skin comes into contact with an irritant.

Who: Anybody, but allergies are a risk factor.

Cause: Seasonal allergies; allergies to cheap jewelry (generally with nickel), cosmetics, detergents, medications, tattoo pigments, etc.

Symptoms: Itching, redness, swelling.

Contagious? No.

Treatment: Remove the irritant, and avoid future contact.

DANDRUFF

A type of dermatitis (seborrheic) that mainly affects the scalp.

Who: Mostly people with genetic predispositions, immune or nutrition issues.

Cause: Genetics, environmental factors, dry skin, stress.

Symptoms:Itching, flaking, discoloration of the skin.

Contagious? No.

Treatment: Medicated dandruff shampoo; shampoo daily; eat a healthy diet; get some sun; apply tea tree oil. Seek prescription treatments if the above doesnt help.

ECZEMA

Think of this chronic skin condition like asthma of the skin. Skin can be normal, and then suffer from outbreaks, like an allergic reaction.

Who: Anybody, but those with asthma or allergies are at higher risk.

Cause: Genetics, skin irritation or damage, immune issues.

Symptoms: Dryness, redness, itching, cracking, bleeding, infection.

Contagious? No.

Treatment: Hydrocortisone, antihistamines, steroid creams, laser therapy, immunosuppressants.

KERATOSIS PILARIS

An inherited skin condition that can make the upper arms, thighs, buttocks and/or cheeks appear to have goosebumps or whiteheads.

Cause: Genetics, worsened by dry environments.

Who: More common in children and young adults and generally resolves itself with age.

Symptoms: Painless, but can cause bumps and coarse skin.

Contagious? No.

Treatment: Exfoliate and moisturize; salicylic acid, topical retinoids.

MOLES

Mostly everybody has a mole somewhere or other. Generally, these pigmented skin growths are harmless, but some can be risk factors for melanoma (skin cancer).

Who: Almost everybody.

Cause: Irregular or clumpy growth of pigmented skin cells.

Symptoms: Beware of moles that are asymmetrical, oddly shaped, multicolored, larger than a pencil eraser and/or quickly changing, as these can be signs of melanoma.

Contagious? No.

Treatment: If your moles seem irregular, see a doctor immediately. Most moles dont require treatment, but if needed, they can be surgically removed by a dermatologist. In general, its a good idea to monitor your moles over time, just to make sure they dont turn against you.

MOLLUSCUM CONTAGIOSUM

This skin disease is caused by a poxvirus that lives in the upper layer of the skin.

Who: Anybody, but people with compromised immune systems are at higher risk.

Cause: Viral infection spread via physical contact (either skin-to-skin or via shared objects, such as towels or toys).

Symptoms: Itching, redness, small bumps with a pearly appearance.

Contagious? Yes, but your body can completely clear the infection.

Treatment: The disease typically clears on its own in six months to four years. A medical professional can help remove the lesions; do not attempt on your own.

PSORIASIS

Skin generally takes weeks to grow, but with this skin condition, it grows at hyperspeed, causing significant irritation.

Who: Genetics combined with triggering events such as stress, weather and/or medication.

Cause: An overactive immune system, generally.

Symptoms: Most people develop plaque psoriasis, which consists of scaly, raised patches that can look silver. They are very itchy, but scratching makes it worse. Other types of psoriasis include rashes and irritation on different parts of the body.

Contagious? No.

Treatment: Prescription medication, including lotions, pills and injections.

ROSACEA

Santa Claus is famous for his rosy cheeks. But what you took for Christmas cheer is most likely the skin condition rosacea.

Who: Older people, mostly women, with fair skin.

Cause: Genetics, acne is a risk factor, spicy foods, stress, sunlight.

Symptoms: Redness on the cheeks and nose, enlarged blood vessels, hot skin, irritated eyes, swollen nose.

Contagious? No.

Treatment: Antibiotics, laser therapy, surgery.

WARTS

A skin growth caused by the human papillomavirus (HPV).

Who: Anybody, but nail biting, hangnails, broken skin, shaving and weakened immune systems are risk factors.

Cause: Physical contact (skin-to-skin or with a contaminated object).

Symptoms: Depending on the type of wart, the growth can appear on the hands, fingers, feet, face, genitals and, really, anywhere.

Contagious? Yes.

Treatment: Can eventually resolve on its own; over-the-counter treatments available; dermatologist can treat with excision, electrosurgery, cryotherapy and more.

This story appeared in Las VegasWeekly.

Continued here:

How to identify and treat strange things that might be happening on your skin - Las Vegas Sun

Psoriatic arthritis and psoriasis have high economic burdens and the total annual costs were similar between the 2 diseases, but the combination of both yielded the highest costs, according to an abstract published at the European League Against Rheumatism annual meeting.

The researchers analyzed 318 patients with psoriasis (n = 196), PsA (n = 43), or both (n = 79) in the COEPSO (Evaluation of Costs in patients with Psoriatic Disease) trial, an observational, retrospective, cross-sectional study in 22 Spanish centers from February 2017 to February 2018.

The authors obtained information from the year prior to the study on direct nonhealth care services (including social services, home care, and private health and nonhealth professionals), as well as indirect and total costs (direct nonhealth care and indirect costs) related to the disease. They calculated out-of-pocket costs, which were specified directly by the patients, and loss of productivity costs, which were gauged by the average salaries for the occupation specific by the patients.

Patients with both psoriasis and PsA had higher annual total costs than patients who only had 1 disease (75.5% higher than patients with psoriasis and 60.9% higher than patients with PsA). However, the total costs for patients with psoriasis and PsA were similar.

The average annual total cost per patient was 1042.71 ($1186.64) for psoriasis, 1137.84 ($1294.90) for PsA, and 1830.26 ($2082.89) for both. The breakdown of direct nonhealth care costs vs indirect costs were:

PsA and [psoriasis] have proved to be diseases with a high economic burden, and the total costs were mainly driven by direct non-healthcare costs, the authors concluded.

Reference

Vincente E, Castaeda S, Llamas Velasco M, et al. Cost of illness in patients with psoriasis and psoriatic arthritis. COEPSO Study. Presented at: EULAR 2020; June 3-6, 2020; Abstract OP0262-HPR. https://ard.bmj.com/content/79/Suppl_1/164.2

Follow this link:

Indirect Nonhealth Care Costs Drive Total Costs in Psoriatic Arthritis and Psoriasis - AJMC.com Managed Markets Network

The story so far: On July 11, pharma major Biocon announced that it had received the approval of the Drugs Controller General of India (DCGI) to market Itolizumab for treatment of cytokine release syndrome (CRS) in moderate to severe acute respiratory distress syndrome patients due to COVID-19. Itolizumab is a monoclonal antibody which is used to treat acute psoriasis.

Monoclonal antibodies are proteins cloned in the lab to mimic antibodies produced by the immune system to counter an infection. They have their genesis in serum, the colourless constituent of blood that contains antibodies. These proteins bind to an antigen, the fragment of an infectious virus in the case of SARS-CoV-2, and either destroy it or block its action. In the case of COVID-19, there are yet no proven drugs to treat moderate or severe manifestations of the disease. Among the therapies being tested is convalescent plasma, which is a constituent of blood and recovered from those who have successfully fought the disease. This blood contains antibodies produced within a week or two of being infected. While plasma therapy involves injecting this entire antibody-soup into another sick patient, a monoclonal antibody can be made by isolating specific antibodies and multiplying them via various techniques. Isolating plasma and serum is laborious and time-consuming when it must be administered to every patient. However, since 1975, several techniques have been perfected that allow antibodies once isolated to be easily replicated. These are stored in vials and can be injected into patients.

Also read | Biocons COVID-19 drug tested on too few patients to reliably conclude on benefits, say experts

While eight in 10 of those infected by the disease recover with little more than a few days of cough and fever, about one in 10 can manifest severe systems of the disease irrespective of their age and medical history. Experts are not sure why, but have observed that many who died were victims of a cytokine storm when the immune system goes into overdrive to flush out the virus. Pro-inflammatory cytokines recruit a host of specialised immune system cells to neutralise antigens. However, these cytokines can aggravate inflammation and injury in lung cells as well as in several other organs. A challenge in treatment is how to prevent this over-reaction. One method is to use antibodies that can block a particular protein, called CD6. They are found on the surface of T-cells, a class of cells that are a central prong in the bodys defence system.

Experts say if this CD-6 is suppressed, it will prevent the T-cells from releasing a cytokine cascade and thus better regulate the immune system. There is also a lot of research going on in using such antibodies to prevent the replication of the virus. Since last month there have been reports from laboratories from nearly everywhere, reporting the presence of one or more antibodies that could be used to block the spike protein, the key the coronavirus uses to infiltrate lung cells and proliferate. Before monoclonal antibodies were roped into discussions surrounding COVID-19, research has focused on deriving the right kind of antibodies that specifically bind onto regions of interest. These underpin the design of cancer therapies or fixes for autoimmune diseases, rheumatoid arthritis or acute psoriasis.

Sometimes antibodies are known to help viral entry and replication in target cells which can worsen the disease. This is why they need careful evaluation.

Also read | No evidence yet that itolizumab, tocilizumab reduces deaths: ICMR head

Itolizumab is an approved drug for acute psoriasis since 2013 and has passed safety and efficacy trials for that disease in over 500 patients. However, independent experts have pointed out that the efficacy of the drug in treating COVID-caused Acute Respiratory Disease Syndrome has not been conclusively demonstrated because it has, as part of a clinical trial, only been tested on 30 patients. However, the drug has been approved by the DCGI for emergency use in the treatment of moderate to severely-ill patients as per the discretion of physicians. The DCGI also directed Biocon to conduct a phase-4 study it must monitor it for adverse reactions or side-effects after it has been administered in large groups of patients and report back to the authorities. Experts pointed out that the normal process for approving a drug includes a phase-3 trial, where the drugs safety and efficacy are first evaluated in the wider population. Officials at Biocon claim they plan to test the drug in the United States, Canada, Australia and New Zealand. Several doctors, at a press conference organised by Biocon, said their patients had benefitted from the drug but mostly when they were yet to reach a stage before requiring ventilators or external oxygen support. The drug cost a little under 8,000 for every vial. Generally, four vials are necessary for treatment, company officials said.

You have reached your limit for free articles this month.

To get full access, please subscribe.

Already have an account ? Sign in

Show Less Plan

Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.

Move smoothly between articles as our pages load instantly.

Enjoy reading as many articles as you wish without any limitations.

A one-stop-shop for seeing the latest updates, and managing your preferences.

A select list of articles that match your interests and tastes.

We brief you on the latest and most important developments, three times a day.

*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.

Follow this link:

The Hindu Explains | Why is a psoriasis drug being used to treat COVID-19 patients? - The Hindu

The global Psoriasis market focuses on encompassing major statistical evidence for the Psoriasis industry as it offers our readers a value addition on guiding them in encountering the obstacles surrounding the market. A comprehensive addition of several factors such as global distribution, manufacturers, market size, and market factors that affect the global contributions are reported in the study. In addition the Psoriasis study also shifts its attention with an in-depth competitive landscape, defined growth opportunities, market share coupled with product type and applications, key companies responsible for the production, and utilized strategies are also marked.

This intelligence and 2026 forecasts Psoriasis industry report further exhibits a pattern of analyzing previous data sources gathered from reliable sources and sets a precedented growth trajectory for the Psoriasis market. The report also focuses on a comprehensive market revenue streams along with growth patterns, analytics focused on market trends, and the overall volume of the market.

Moreover, the Psoriasis report describes the market division based on various parameters and attributes that are based on geographical distribution, product types, applications, etc. The market segmentation clarifies further regional distribution for the Psoriasis market, business trends, potential revenue sources, and upcoming market opportunities.

Download PDF Sample of Psoriasis Market report @ https://hongchunresearch.com/request-a-sample/40648

Key players in the global Psoriasis market covered in Chapter 4:, Celgene Corporation, Takeda Pharmaceutical Company Limited, Pfizer Inc., Stiefel Laboratories Inc., Amgen Inc., Biogen Idec, Novartis AG, Eli Lilly and Company, Johnson and Johnson (Janssen Biotech Inc.), AbbVie Inc.

In Chapter 11 and 13.3, on the basis of types, the Psoriasis market from 2015 to 2026 is primarily split into:, Systemic, Phototherapy, Topical Treatment, Others

In Chapter 12 and 13.4, on the basis of applications, the Psoriasis market from 2015 to 2026 covers:, Injectable, Tropical, Oral

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:, North America (Covered in Chapter 6 and 13), United States, Canada, Mexico, Europe (Covered in Chapter 7 and 13), Germany, UK, France, Italy, Spain, Russia, Others, Asia-Pacific (Covered in Chapter 8 and 13), China, Japan, South Korea, Australia, India, Southeast Asia, Others, Middle East and Africa (Covered in Chapter 9 and 13), Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Others, South America (Covered in Chapter 10 and 13), Brazil, Argentina, Columbia, Chile, Others

The Psoriasis market study further highlights the segmentation of the Psoriasis industry on a global distribution. The report focuses on regions of North America, Europe, Asia, and the Rest of the World in terms of developing business trends, preferred market channels, investment feasibility, long term investments, and environmental analysis. The Psoriasis report also calls attention to investigate product capacity, product price, profit streams, supply to demand ratio, production and market growth rate, and a projected growth forecast.

In addition, the Psoriasis market study also covers several factors such as market status, key market trends, growth forecast, and growth opportunities. Furthermore, we analyze the challenges faced by the Psoriasis market in terms of global and regional basis. The study also encompasses a number of opportunities and emerging trends which are considered by considering their impact on the global scale in acquiring a majority of the market share.

The study encompasses a variety of analytical resources such as SWOT analysis and Porters Five Forces analysis coupled with primary and secondary research methodologies. It covers all the bases surrounding the Psoriasis industry as it explores the competitive nature of the market complete with a regional analysis.

Brief about Psoriasis Market Report with [emailprotected] https://hongchunresearch.com/report/psoriasis-market-40648

Some Point of Table of Content:

Chapter One: Report Overview

Chapter Two: Global Market Growth Trends

Chapter Three: Value Chain of Psoriasis Market

Chapter Four: Players Profiles

Chapter Five: Global Psoriasis Market Analysis by Regions

Chapter Six: North America Psoriasis Market Analysis by Countries

Chapter Seven: Europe Psoriasis Market Analysis by Countries

Chapter Eight: Asia-Pacific Psoriasis Market Analysis by Countries

Chapter Nine: Middle East and Africa Psoriasis Market Analysis by Countries

Chapter Ten: South America Psoriasis Market Analysis by Countries

Chapter Eleven: Global Psoriasis Market Segment by Types

Chapter Twelve: Global Psoriasis Market Segment by Applications12.1 Global Psoriasis Sales, Revenue and Market Share by Applications (2015-2020)12.1.1 Global Psoriasis Sales and Market Share by Applications (2015-2020)12.1.2 Global Psoriasis Revenue and Market Share by Applications (2015-2020)12.2 Injectable Sales, Revenue and Growth Rate (2015-2020)12.3 Tropical Sales, Revenue and Growth Rate (2015-2020)12.4 Oral Sales, Revenue and Growth Rate (2015-2020)

Chapter Thirteen: Psoriasis Market Forecast by Regions (2020-2026) continued

Check [emailprotected] https://hongchunresearch.com/check-discount/40648

List of tablesList of Tables and FiguresTable Global Psoriasis Market Size Growth Rate by Type (2020-2026)Figure Global Psoriasis Market Share by Type in 2019 & 2026Figure Systemic FeaturesFigure Phototherapy FeaturesFigure Topical Treatment FeaturesFigure Others FeaturesTable Global Psoriasis Market Size Growth by Application (2020-2026)Figure Global Psoriasis Market Share by Application in 2019 & 2026Figure Injectable DescriptionFigure Tropical DescriptionFigure Oral DescriptionFigure Global COVID-19 Status OverviewTable Influence of COVID-19 Outbreak on Psoriasis Industry DevelopmentTable SWOT AnalysisFigure Porters Five Forces AnalysisFigure Global Psoriasis Market Size and Growth Rate 2015-2026Table Industry NewsTable Industry PoliciesFigure Value Chain Status of PsoriasisFigure Production Process of PsoriasisFigure Manufacturing Cost Structure of PsoriasisFigure Major Company Analysis (by Business Distribution Base, by Product Type)Table Downstream Major Customer Analysis (by Region)Table Celgene Corporation ProfileTable Celgene Corporation Production, Value, Price, Gross Margin 2015-2020Table Takeda Pharmaceutical Company Limited ProfileTable Takeda Pharmaceutical Company Limited Production, Value, Price, Gross Margin 2015-2020Table Pfizer Inc. ProfileTable Pfizer Inc. Production, Value, Price, Gross Margin 2015-2020Table Stiefel Laboratories Inc. ProfileTable Stiefel Laboratories Inc. Production, Value, Price, Gross Margin 2015-2020Table Amgen Inc. ProfileTable Amgen Inc. Production, Value, Price, Gross Margin 2015-2020Table Biogen Idec ProfileTable Biogen Idec Production, Value, Price, Gross Margin 2015-2020Table Novartis AG ProfileTable Novartis AG Production, Value, Price, Gross Margin 2015-2020Table Eli Lilly and Company ProfileTable Eli Lilly and Company Production, Value, Price, Gross Margin 2015-2020Table Johnson and Johnson (Janssen Biotech Inc.) ProfileTable Johnson and Johnson (Janssen Biotech Inc.) Production, Value, Price, Gross Margin 2015-2020Table AbbVie Inc. ProfileTable AbbVie Inc. Production, Value, Price, Gross Margin 2015-2020Figure Global Psoriasis Sales and Growth Rate (2015-2020)Figure Global Psoriasis Revenue ($) and Growth (2015-2020)Table Global Psoriasis Sales by Regions (2015-2020)Table Global Psoriasis Sales Market Share by Regions (2015-2020)Table Global Psoriasis Revenue ($) by Regions (2015-2020)Table Global Psoriasis Revenue Market Share by Regions (2015-2020)Table Global Psoriasis Revenue Market Share by Regions in 2015Table Global Psoriasis Revenue Market Share by Regions in 2019Figure North America Psoriasis Sales and Growth Rate (2015-2020)Figure Europe Psoriasis Sales and Growth Rate (2015-2020)Figure Asia-Pacific Psoriasis Sales and Growth Rate (2015-2020)Figure Middle East and Africa Psoriasis Sales and Growth Rate (2015-2020)Figure South America Psoriasis Sales and Growth Rate (2015-2020)Figure North America Psoriasis Revenue ($) and Growth (2015-2020)Table North America Psoriasis Sales by Countries (2015-2020)Table North America Psoriasis Sales Market Share by Countries (2015-2020)Figure North America Psoriasis Sales Market Share by Countries in 2015Figure North America Psoriasis Sales Market Share by Countries in 2019Table North America Psoriasis Revenue ($) by Countries (2015-2020)Table North America Psoriasis Revenue Market Share by Countries (2015-2020)Figure North America Psoriasis Revenue Market Share by Countries in 2015Figure North America Psoriasis Revenue Market Share by Countries in 2019Figure United States Psoriasis Sales and Growth Rate (2015-2020)Figure Canada Psoriasis Sales and Growth Rate (2015-2020)Figure Mexico Psoriasis Sales and Growth (2015-2020)Figure Europe Psoriasis Revenue ($) Growth (2015-2020)Table Europe Psoriasis Sales by Countries (2015-2020)Table Europe Psoriasis Sales Market Share by Countries (2015-2020)Figure Europe Psoriasis Sales Market Share by Countries in 2015Figure Europe Psoriasis Sales Market Share by Countries in 2019Table Europe Psoriasis Revenue ($) by Countries (2015-2020)Table Europe Psoriasis Revenue Market Share by Countries (2015-2020)Figure Europe Psoriasis Revenue Market Share by Countries in 2015Figure Europe Psoriasis Revenue Market Share by Countries in 2019Figure Germany Psoriasis Sales and Growth Rate (2015-2020)Figure UK Psoriasis Sales and Growth Rate (2015-2020)Figure France Psoriasis Sales and Growth Rate (2015-2020)Figure Italy Psoriasis Sales and Growth Rate (2015-2020)Figure Spain Psoriasis Sales and Growth Rate (2015-2020)Figure Russia Psoriasis Sales and Growth Rate (2015-2020)Figure Asia-Pacific Psoriasis Revenue ($) and Growth (2015-2020)Table Asia-Pacific Psoriasis Sales by Countries (2015-2020)Table Asia-Pacific Psoriasis Sales Market Share by Countries (2015-2020)Figure Asia-Pacific Psoriasis Sales Market Share by Countries in 2015Figure Asia-Pacific Psoriasis Sales Market Share by Countries in 2019Table Asia-Pacific Psoriasis Revenue ($) by Countries (2015-2020)Table Asia-Pacific Psoriasis Revenue Market Share by Countries (2015-2020)Figure Asia-Pacific Psoriasis Revenue Market Share by Countries in 2015Figure Asia-Pacific Psoriasis Revenue Market Share by Countries in 2019Figure China Psoriasis Sales and Growth Rate (2015-2020)Figure Japan Psoriasis Sales and Growth Rate (2015-2020)Figure South Korea Psoriasis Sales and Growth Rate (2015-2020)Figure Australia Psoriasis Sales and Growth Rate (2015-2020)Figure India Psoriasis Sales and Growth Rate (2015-2020)Figure Southeast Asia Psoriasis Sales and Growth Rate (2015-2020)Figure Middle East and Africa Psoriasis Revenue ($) and Growth (2015-2020) continued

About HongChun Research:HongChun Research main aim is to assist our clients in order to give a detailed perspective on the current market trends and build long-lasting connections with our clientele. Our studies are designed to provide solid quantitative facts combined with strategic industrial insights that are acquired from proprietary sources and an in-house model.

Contact Details:Jennifer GrayManager Global Sales+ 852 8170 0792[emailprotected]

NOTE: Our report does take into account the impact of coronavirus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.

Originally posted here:

Analyzing Impacts Of COVID-19 On Psoriasis Market Effects, Aftermath And Forecast To 2026 - Cole of Duty

Candidates in the LEO PDE4 inhibitor compound series have demonstrated potential to become best-in-class based on Phase 2 studies in psoriasis (oral) and atopic dermatitis (topical)

PDE4 compound series strengthens UNIONs pipeline and offers potential synergies at organizational, financial and commercial levels

Hellerup, Denmark, July 21, 2020 UNION therapeutics A/S (UNION) today announced the completion of a transaction with LEO Pharma A/S (LEO Pharma) to acquire the global rights for the LEO PDE4 inhibitor compound series to be re-named UNI500.

UNI500 is a series of phosphodiesterase type 4 (PDE4) inhibitors that were discovered by LEO Pharma. LEO Pharma has been developing candidates from this series from discovery into Phase 2 in psoriasis (orismilast, oral) and atopic dermatitis (orismilast, topical) and in both indications demonstrated superior effect over placebo in randomized, double-blinded, placebo-controlled clinical studies.

The acquisition of the PDE4 inhibitor compound series is perfectly aligned with UNIONs vision to build a sustainable pharmaceutical company and it complements our current clinical activities in immuno-dermatology. The acquisition substantially accelerates our growth trajectory and enables synergies at organizational, financial, and commercial levels. Above and beyond that, UNION considers compounds from the PDE4 inhibitor compound series to have best-in-class potential for the treatment of psoriasis and other immune-dermatological disorders, with an overarching aim to address unmet medical needs, said Rasmus Toft-Kehler, Chief Executive Officer of UNION.

Morten Sommer, Chief Scientific Officer, of UNION explains Orismilast has demonstrated promising effects in clinical studies suggesting that it could become an attractive oral treatment option for patients with psoriasis and other immune-dermatological disorders. Our ambition, based on demonstrated potency levels, is to develop orismilast as a best-in-class PDE4 inhibitor across multiple immune-related diseases. As a next step, UNION will finalize formulation efforts with orismilast and simultaneously evaluate priority indications for clinical advancement.

Thorsten Thormann, Vice President, Global Research at LEO Pharma added LEO Pharma has been working very closely with the UNION team and have been impressed with their approach and professionalism in dermatological drug development. Accordingly, when the strategic decision was taken to divest the LEO PDE4 inhibitor compound series and orismilast, UNION was an obvious partner of choice for LEO Pharma. We look forward to seeing the program moving forward for the benefit of patients in need of new treatment options.

Under the agreement, UNION will pay upfront, development and commercial milestones of up to 200 million USD, plus low single-digit royalties on sales. As part of the transaction, LEO Pharma also becomes a minority shareholder in UNION therapeutics.

About UNION therapeutics A/SUNION therapeutics A/S is a privately held, clinical stage, pharmaceutical company dedicated to the development of novel treatments for inflammatory and infectious diseases. The company is working on two complementary chemistry classes spanning immunology and microbiology and has three candidates in clinical development. UNION is headquartered in Hellerup (Denmark) and managed by an experienced team across Europe and USA.

About LEO Pharma A/S

The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 92 million patients in 130 countries.

ContactsMorten BoesenChief Financial Officer

Tel: +45 2381 5487

Email: info@uniontherapeutics.com

JW Communications

Julia Wilson

Tel: +44 781 8430877

Email: communications@uniontherapeutics.com

See the article here:

UNION therapeutics announces acquisition of PDE4i compound class from LEO Pharma with oral lead candidate (orismilast) in Phase 2 - PharmiWeb.com

Global Systemic Psoriasis Therapeutics market Size study report with COVID-19 effect is considered to be an extremely knowledgeable and in-depth evaluation of the present industrial conditions along with the overall size of the Systemic Psoriasis Therapeutics industry, estimated from 2020 to 2026. The research report also provides a detailed overview of leading industry initiatives, potential market share and business-oriented planning, etc. The study discusses favorable factors related to current industrial conditions, levels of growth of the Systemic Psoriasis Therapeutics industry, demands, differentiable business-oriented approaches used by the manufacturers of the Systemic Psoriasis Therapeutics industry in brief about distinct tactics and futuristic prospects.

The research report on Systemic Psoriasis Therapeutics market provides a comparative study of the historical data with the changing market scenario to reveal the future roadmap of the industry. It offers detailed insights pertaining to the growth markers, challenges and opportunities residing in this industry vertical. A magnified view of the regional landscape and competitive terrain of this business sphere is also encompassed in the document. In addition, the report reevaluates the market behavior considering the impact of COVID-19 on the business landscape.

Request Sample Copy of this Report @ https://www.cuereport.com/request-sample/24302

Systemic Psoriasis Therapeutics market rundown:

Request Sample Copy of this Report @ https://www.cuereport.com/request-sample/24302

An overview of regional terrain:

Competitive outlook of the Systemic Psoriasis Therapeutics market:

Other important takeaways from the Systemic Psoriasis Therapeutics market report:

The report answers important questions that companies may have when operating in the global Systemic Psoriasis Therapeutics market. Some of the questions are given below:

What will be the size of the global Systemic Psoriasis Therapeutics market in 2026?

What is the current CAGR of the global Systemic Psoriasis Therapeutics market?

Which product is expected to show the highest market growth?

Which are the top players currently operating in the global Systemic Psoriasis Therapeutics market?

Which application is projected to gain a lions share of the global Systemic Psoriasis Therapeutics market?

Will there be any changes in market competition during the forecast period?

Which region is foretold to create the most number of opportunities in the global Systemic Psoriasis Therapeutics market?

Request Customization on This Report @ https://www.cuereport.com/request-for-customization/24302

See the original post here:

Global Systemic Psoriasis Therapeutics Market Development and Trends Forecasts Report 2020-2026 - CueReport

On this page:BasicsTopical MedicationsOral TreatmentsBiologics

Theres no cure for psoriasis, but there are a lot of medications that can treat the chronic skin condition. Whether youre newly diagnosed or still searching for the right treatment (yup, sometimes theres a little trial and error), the number of choices can seem daunting. There are topicals, oral medications, and biologic drugs. While they all have the same overall goalclear your skinthey do it in different ways. Some medications soothe and calm an outbreak, while others prevent future flares. The treatment plan you end up on is often determined by your type of psoriasis, its severity and location, and your overall healthy history. Here, well walk you through all your options.

Psoriasis is a chronic condition that causes red, stinging patches or bumps on your arms, legs, and even your scalp. When you have this disease, your skin cells turn over faster than they should, leading to a buildup of cells on your body's surface that turn into those inflamed, scaly spots.

At first glance, it looks like a skin issue. And while thats true, experts say it starts on a deeper levelin your immune system. An overactive immune system, along with a genetic predisposition for psoriasis, and at least one other factor such as infection, obesity, or smoking are thought to be the driving forces behind the condition.

As we mentioned, there are several different types of psoriasis: plaque psoriasis (the most common type), scalp psoriasis, guttate, pustular, inverse, erythrodermic, and even psoriatic arthritis, which is a combo of psoriasis and arthritis. The medication youre prescribed is often determined by your type, and may include topical treatments, drugs taken orally, and injections. Let's start by taking a look at topical medications for psoriasis.

These creams, ointments, foams, shampoos, and lotions are applied directly to the affected areas, and are often prescribed for mild to moderate casespsoriasis that covers 1% to 10% of your body. Topical treatments can be used alone, or in combination with another treatment prescribed by your doctor. For example, you may use a cream along with an oral medication and/or light therapy. Topicals are used for these types of psoriasis:

The most common types of topical treatments prescribed for psoriasis include:

Corticosteroids work by reducing inflammation and redness. Theyre often prescribed to clear a current flare but wont necessarily stop your psoriasis from coming back in the future. There are various forms, including liquids, foams, and creams that come in various strengths. Examples include:

Side effects include:

These creams, liquids, and foams are believed to stop the overgrowth of skin cells, which may help prevent future psoriasis flares. They also help clear current patches by sloughing off scaly skin and flattening plaques so they are less noticeable.

Dovonex (calcipotriene) is a synthetic form of vitamin D that comes in a cream or a liquid for scalp psoriasis. You apply it twice a day for up to eight weeks.

Vectical (calcitriol) is a natural form of vitamin D that comes in an ointment formulation to use twice daily. While most topicals are okay to use during pregnancy, Vectical is not.

Enstilar (calcipotriene and betamethasone dipropionate) is a foam thats a combination of a synthetic form of vitamin D and a steroid. Its approved for adults only and used once a day for up to a month.

Taclonex (calcipotriene and betamethasone dipropionate) is a liquid vitamin D-steroid combo thats approved for use in children ages 12 and up. Use it once a day for up to a month.

Research has shown that using a vitamin D analogue with a corticosteroid may not only be more effective than using either one alone, but the combo can even reduce the side effects that can come with strong steroid use. But side effects can include:

Yes, the vitamin A derivatives that smooth wrinkles and clear acne can also help with psoriasis. Topical retinoids help alleviate redness, scaling, and inflammation, and regulate the high-speed skin-cell growth associated with the condition. Because of their risk of birth defects, retinoids should be avoided if youre pregnant or planning to become pregnant.

Tazorac (tazarotene), available as a gel or cream, is approved for adults and comes in two strengths. It is used once a day and can be applied daily for up to a year.

Duobrii (halobetasol propionate and tazarotene) is one of the newest topical medications. This combo product contains a vitamin A derivative (called tazarotene) with an anti-inflammatory lotion. You use it daily as needed.

Side effects include:

Anthralin is a man-made version of goa powder, a natural substance that comes from the araroba tree. Like many of the other topicals, this helps halt the excessive growth of skin cells and is approved for adults. It comes in a variety of formulations including a cream, ointment, and paste which can be used once a day on the skin. It also comes in a shampoo which can be used on the scalp. Anthralin-containing products include:

Side effects include:

Taken by mouth, oral medications target your overactive immune system (or parts of it) to reduce inflammation and/or slow down skin cell production. With so many choices, your doctor can help you find the best oral option for you to take alone or in combination with other forms of treatment like topicals, phototherapy, or biologics. Oral medications are most often prescribed for the following psoriasis types:

The most commonly prescribed oral options include:

Trexall and Rheumatrex (methotrexate) work by targeting and slowing the growth of skin cells. They come with a risk of toxicity, so theyre only taken once or twice a week, and not prescribed for long-term use. Methotrexate isnt safe to take if youre pregnant or nursing or have any blood issues like low white blood cell count or anemia.

Side effects include:

Gengraf (cyclosporine) was initially used as a medication to ward off organ rejection. It works on severe psoriasis by slowing an overactive immune system. The drug is taken daily either in pill form or a liquid that you dilute in juice.

Side effects: Cyclosporine can cause decreased kidney function, flu-like symptoms, high blood pressure, and cholesterol. This is another medication thats not safe while pregnant or nursing, and shouldnt be taken for longer than a year. Avoid cyclosporine if you take anti-cancer, anti-fungal, anti-convulsants, or anti-inflammatory medications, as well as antibiotics, aspirin, or ibuprofen.

Xeljanz (tofacitinib), one of the newer oral medications, inhibits a family of intracellular nonreceptors called Janus kinase, a.k.a. a JAK inhibitor. In doing so, it decreases cytokines, proteins that cause inflammation. By lowering inflammation in those with psoriasis, you get less symptoms.

Side effects include:

Soriatane (acitretin) is a form of vitamin A (a.k.a. a retinoid) that helps regulate those out-of-control skin cells. Its taken orally daily. If youre pregnant or planning to start a family within the next three years or have experienced sensitivity to retinoids in the past, this medication isnt an option for you.

Side effects include:

Otezla (apremilast) is one of the newest oral treatments. It works by reducing inflammation. Less inflammation may mean less outbreaks, or at least less severe ones. This cant be taken with some other medications such as phenobarbital and rifampin.

Side effects include:

Prednisone and Medrol (methylprednisone). Sometimes prescribed as pills or injections, these meds work by reducing inflammation and slowing cell growth. They help calm a flare-up but arent recommended for long-term use.

Side effects include:

These drugs are commonly prescribed (alone or along with other meds) for moderate-to-severe psoriasis because theyre so effectiveespecially the newer kids on the block like Skyrizi, Cimzia, and Ilumya.

Biologics are known as systemic treatments because they spread throughout the body and do their work from the inside out, but unlike other drugs that affect your entire immune system, these zero in on very specific partsvarious proteins or white blood cells that contribute to psoriasis such as tumor necrosis factor (TNF), interleukin 17, interleukin 23, and T-cells. By blocking these proteins and cells, the drugs can stop a psoriasis flare.

Interestingly, psoriasis biologics may help with other inflammatory issues such as heart disease. A recent study in JAMA Cardiology found that those who took biologics for psoriasis had a significant reduction in coronary inflammation, too.

Biologics are made from living cells of animals, humans, or bacteria and are given through an intravenous drip (IV) or injected in your thigh, upper arm, stomach, or butt either by a health care provider, caregiver, or yourself. (Dont worry, your M.D. will make sure you know exactly how to do this before sending you off to self-inject.)

Theyre used to treat these types of psoriasis:

There are several types of biologics:

Stelara (ustekinumab) is injected into your body to block a protein called IL-23 and IL-12. This helps ease the inflammation that can cause symptoms of both moderate to severe psoriasis and psoriatic arthritis. The drug requires two starter injections four weeks apart followed by four doses per year done 12 weeks apart.

Ilumya (tidrakizumab-asmn) and Skyrizi (risankizumab-rzaa) require two initial doses, four weeks apart, to block the IL-23 protein. This is followed by four doses per year, every 12 weeks.

Tremfya (guselkumab) also targets IL-23 with two starter doses four weeks apart and then every eight weeks.

Side effects are rare but include:

One cause of plaque psoriasis (which accounts for 80% of all psoriasis cases) is the excess production of a protein called tumor necrosis factor (TNF) which tells your skin cells to grow at an accelerated rate. These medications, which block TNF so that your skin cells grow more slowly, need to be taken over a long period of time to clear your skin.

Unlike some psoriasis medications, TNF inhibitors can be taken while pregnant or nursing (but of course, not without talking to your OB/GYN). However, youll want to avoid this category of biologics if you have multiple sclerosis (MS) or have an immediate relative with MS. Anti-TNF therapy has been associated with the demyelinating disease.

Cimzia (certolizumab pegol) can either be injected by yourself or you can have it injected at your doctors offices with two doses the first time, then two doses two weeks later, followed by two doses two weeks after that. Following these initial shots, you have one every other week.

Enbrel (etanercept) is unique because it is also approved for use in children. Although dosage can vary, you typically inject yourself with Enbrel twice a week for the first three months and then once a week for three months after that.

Humira (adalimumab) starts with two doses on day one and continues with one dose every other week. Cyltezo and Amjevita are approved biosimilars to Humira.

Remicade (infliximab) is given as an IV infusion that takes about two hours at your health care providers office. You begin with three starter doses administered during a six-week period, and then get one infusion every eight weeks. Inflectra and Renflexis are biosimilar.

Side effects are rare but include:

These biologics contain a human antibody that blocks a protein called interleukin 17 (IL 17), which causes inflammation and an immune response. Before prescribing these biologics, your M.D. will make sure you dont have latent tuberculosis, meaning you carry the tuberculosis bacteria but dont have an active disease. IL 17 inhibitors can trigger a case.

Cosentyx (secukinumab) is self-injected; two doses a week for four weeks and then once a month.

Siliq (brodalumab) targets four of the IL-17 proteins (others target just one). You take one dose weekly for three weeks and then one dose every two weeks. (Siliq carries a warning about suicidal behavior and thoughts.

Taltz (ixekizumab) is self-injected; two doses on the first day and then one injection every two weeks for three months. After that, you do it just once per month.

Side effects are rare but include:

These medications target T-cells, a type of white blood cell that causes inflammation.

Orencia (abatacept) is prescribed as a once-a-week shot for psoriatic arthritis, but it doesnt help with skin psoriasis.

Side effects include:

In some cases, your physician may prescribe a biologic along with another medication such as a topical treatment or oral medication. Some people develop anti-drug antibodies (ADAs) to biologics, making them less effective after a while. A review in the British Journal of Dermatology found that combining a biologic with the systemic oral medication methotrexate may help prevent ADAs.

Some medications are safe to take while pregnant or breastfeeding, while others, such as methotrexate, should be avoided. Discuss your options with your doctor so you can create a customized treatment plan.

You may be desperate to try anything to soothe your skin, but skip the fad diets, tanning beds, and Vicks VapoRubtheres little to no research verifying their efficacy, and they can irritate or dry out your skin.

Yes. Many of the medications are approved for both conditions, including the Cimzia, Enbrel, Humira, Stelara, Remicade, Cosentyx, methotrexate, Otezla, and systemic steroids.

Some people notice their biologic doesnt work as well over time. Experts say your body may have outsmarted the drug by creating antibodies against it. If your psoriasis is no longer responding to a certain drug, your doctor will likely switch you to something else.

See the article here:

What Are the Medication Options for Psoriasis? - HealthCentral.com

HELLERUP, Denmark, July 21, 2020 /PRNewswire/ -- UNION therapeutics A/S ("UNION") today announced the completion of a transaction with LEO Pharma A/S (LEO Pharma) to acquire the global rights for the LEO PDE4 inhibitor compound series to be re-named UNI500.

UNI500 is a series of phosphodiesterase type 4 (PDE4) inhibitors that were discovered by LEO Pharma. LEO Pharma has been developing candidates from this series from discovery into Phase 2 in psoriasis (orismilast, oral) and atopic dermatitis (orismilast, topical) and in both indications demonstrated superior effect over placebo in randomized, double-blinded, placebo-controlled clinical studies.

"The acquisition of the PDE4 inhibitor compound series is perfectly aligned with UNION's vision to build a sustainable pharmaceutical company and it complements our current clinical activities in immuno-dermatology. The acquisition substantially accelerates our growth trajectory and enables synergies at organizational, financial, and commercial levels. Above and beyond that, UNION considers compounds from the PDE4 inhibitor compound series to have best-in-class potential for the treatment of psoriasis and other immune-dermatological disorders, with an overarching aim to address unmet medical needs", said Rasmus Toft-Kehler, Chief Executive Officer of UNION.

Morten Sommer, Chief Scientific Officer, of UNION explains "Orismilast has demonstrated promising effects in clinical studies suggesting that it could become an attractive oral treatment option for patients with psoriasis and other immune-dermatological disorders. Our ambition, based on demonstrated potency levels, is to develop orismilast as a best-in-class PDE4 inhibitor across multiple immune-related diseases. As a next step, UNION will finalize formulation efforts with orismilast and simultaneously evaluate priority indications for clinical advancement".

Thorsten Thormann, Vice President, Global Research at LEO Pharma added "LEO Pharma has been working very closely with the UNION team and have been impressed with their approach and professionalism in dermatological drug development. Accordingly, when the strategic decision was taken to divest the LEO PDE4 inhibitor compound series and orismilast, UNION was an obvious partner of choice for LEO Pharma. We look forward to seeing the program moving forward for the benefit of patients in need of new treatment options".

Under the agreement, UNION will pay upfront, development and commercial milestones of up to 200 million USD, plus low single-digit royalties on sales. As part of the transaction, LEO Pharma also becomes a minority shareholder in UNION therapeutics.

About UNION therapeutics A/SUNION therapeutics A/S is a privately held, clinical stage, pharmaceutical company dedicated to the development of novel treatments for inflammatory and infectious diseases. The company is working on two complementary chemistry classes spanning immunology and microbiology and has three candidates in clinical development. UNION is headquartered in Hellerup (Denmark) and managed by an experienced team across Europe and USA.

About LEO Pharma A/SThe company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 92 million patients in 130 countries.

ContactsMorten BoesenChief Financial OfficerTel: +45 2381 5487Email: info@uniontherapeutics.com

JW CommunicationsJulia WilsonTel: +44 781 8430877Email: communications@uniontherapeutics.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/union-therapeutics/r/union-therapeutics-announces-acquisition-of-pde4i-compound-class-from-leo-pharma-with-oral-lead-cand,c3157569

The following files are available for download:

View original content:http://www.prnewswire.com/news-releases/union-therapeutics-announces-acquisition-of-pde4i-compound-class-from-leo-pharma-with-oral-lead-candidate-orismilast-in-phase-2-301096733.html

SOURCE UNION therapeutics

Go here to see the original:

UNION therapeutics announces acquisition of PDE4i compound class from LEO Pharma with oral lead candidate (orismilast) in Phase 2 - BioSpace

Psoriasis is a chronic skin disease in which the immune system triggers the overproduction of skin cells. It causes red, itchy scaly patches that most usually appear on the knees, elbows, trunk and scalp. However, they can develop anywhere on the body. Unfortunately, there is no cure for this condition. Treatments can only help manage symptoms. Psoriasis patches tend to flare up for a few weeks or months, then subside for a while or go into remission. Psoriasis is believed to be caused by immune system malfunction that causes the skin to regenerate at faster than normal rates, but what causes the immune system to malfunction isn't known yet. Both genetics and environmental factors are thought to play a role in the development of Psoriasis. If you have a parent with psoriasis, you are at risk of getting the disease. Some common psoriasis triggers include infections, such as strep throat or skin infections, cold or dry conditions, injury to the skin, smoking and alcohol consumption, stress, certain medications including high blood pressure medications and antimalarial drugs. Some home remedies may help relieve psoriasis symptoms, but it is always advisable to speak to a doctor first. These remedies tend to work best when used in combination with medical treatment.

More:

5 effective home remedies to treat psoriasis - TheHealthSite

Millions of people suffer from psoriasis, an autoimmune disease that causes painful patches of red or scaly skin called plaques to appear on the body. Flares can happen at any time, and they arent limited to spots that are easy to cover. Nor are they treatable with creams or antibiotics like other skin conditions such as eczema. Psoriasis isn't some simple rashIts a lifetime of struggle.

Those are the words of Jassem JasAhmed, a 29-year-old from London whose approach to that struggle is truly inspirational. Jass initial experience with psoriasis is a prime example of just how physically and emotionally debilitating the disease can be. He was diagnosed at 19 and soon found himself with nearly 90 percent of his body covered, and confined to his bed for nine months.

Jass was able to return to his active life, but the flares always returned. Then theyd get better, and then theyd come back, and the cycle would repeat. It still does.

But Jass wouldnt be defeated. After much trial and error and consultation with his doctors, Jass eventually found a course of treatment that suits him and his lifestyle. He also found a creative outlet to vent his anxieties: a vlog and YouTube channel where he chronicles every step of his journey. Jass doesnt sugar-coat anythinghis good days are right there next to his worse flare-ups, in all their high-definition detail. It wasnt long after posting his first video that Jass found himself with subscribers following along, asking for advice, or sending messages of thanks. Psoriasis so often carries embarrassment and shame; Jass shows people suffering from it that they arent alone. An accidental influencer perhaps, but as authentic as they come.

Wear it on your sleeve. Be proud of it, he says. I have psoriasis, it doesnt define me. Its a condition, its not who I am.

Check out the video above to learn more about living with psoriasis and how to retake control when life tries to push you off course.

This content is created and maintained by a third party, and imported onto this page to help users provide their email addresses. You may be able to find more information about this and similar content at piano.io

This commenting section is created and maintained by a third party, and imported onto this page. You may be able to find more information on their web site.

Go here to read the rest:

I Live With Debilitating Psoriasis. Here's How I Don't Let It Defeat Me. - Men's Health

This article was originally published here

Dermatol Ther. 2020 Jun 17:e13858. doi: 10.1111/dth.13858. Online ahead of print.

ABSTRACT

Coronavirus disease (COVID-19) is a highly contagious respiratory infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 outbreak has been declared a pandemic by the World Health Organization on March 2020. The pandemic has affected the management of psoriasis not only for those who are under treatment but also for those who are about to begin a new therapy to control their disease. An increasing number of studies in the current literature have focused on the relationship between psoriasis and COVID-19 from different perspectives. This narrative review includes searching the PubMed and Web of Science databases using the keywords psoriasis, psoriatic arthritis, coronavirus, COVID-19, and SARS-CoV-2. The search was supplemented by manual searching of reference lists of included articles. A total of 11 relevant original investigations and 6 case studies was identified. The search was updated in May 2019. Due to the absence of randomized controlled trials, it is not likely to have a robust evidence-based approach to psoriasis management in the era of COVID-19. However, the current literature may provide some clues for safety considerations. Conventional immunosuppressive therapies such as methotrexate and cyclosporine, and anti-tumor necrosis factor agents should not be preferred due to increased risk of infection, especially in high-risk areas. The use of cyclosporine may pose additional risk due to the side effect of hypertension, which has been reported to be associated with susceptibility to severe COVID-19. Considering that the current literature has provided no conclusive evidence that biologics increase the risk of COVID-19, withdrawal of these agents should be reserved for patients with COVID-19 symptoms. The treatment approach should be personalized, considering the advantages and disadvantages for each case separately.

PMID:32686245 | DOI:10.1111/dth.13858

Continued here:

Psoriasis and COVID-19: A narrative review with treatment considerations - DocWire News

Written by Anuradha Mascarenhas | Pune | Updated: July 21, 2020 7:33:30 am The approval from the DCGI is based on the results from the conclusion of a randomised, controlled clinical trial at hospitals in Mumbai and New Delhi. (Express Photo/Praveen Khanna)

A repurposed drug, Itolizumab, is one of the newest treatments for Covid-19 approved in India. The Drug Controller General of India recently approved it as a novel biologic therapy for restricted emergency use. The decision has also sparked controversy because of the small size of the clinical trials, and because exemption has been granted from phase-III trials.

Itolizumab is an existing drug used for psoriasis, a chronic skin disease involving unregulated growth of some skin cells that develop into red patches mostly on knees and elbows, but also on some other parts of the body. The drug, developed by Bengaluru-based Biocon, was approved in 2013. It is considered safe and effective for the treatment of psoriasis.

Why was it approved for emergency use in Covid treatment?

The SARS-CoV-2 virus has been observed to induce an overreaction of the immune system, generating a large number of cytokines that can cause severe damage to the lungs and other organs, and, in the worst scenario, multi-organ failure and even death.

The approval from the DCGI is based on the results from the conclusion of a randomised, controlled clinical trial at hospitals in Mumbai and New Delhi. The study focused on the safety and efficacy of Itolizumab in preventing cardio-renal complications in Covid-19 patients who also have acute respiratory distress. The drug has been found to reduce these complications in such patients.

Also in Explained | Why community transmission no longer matters at this stage

Basically, the drug controls the hyper-activation of the immune system in response to SARS-CoV-2 virus and prevents morbidity and mortality related to the cytokine storm. The clinical trial showed that the drug is best administered in the pulmonary phase of the Covid-19 infection when the cytokine build up is starting and the patient is experiencing shortness of breath and exhibiting abnormal chest images. It prevents progression to the hyperinflammation phase (cytokine storm) and other complications like coagulation and organ failure, according to Dr Sandeep Athalye, Chief Medical Officer, Biocon Biologics.

The drug has been used over 80 patients in Cuba and off-label in over 150 cases. According to Dr Shashank Joshi, Dean, Indian College of Physicians, the most critical part is to know when to use the drug and it must be reserved for moderate to severe Covid cases with cytokine storm where oxygen requirements are rapidly going up. usually between the 8th day onwards of Covid infection.

What were the results of the trial?

The trial results showed a statistically significant advantage over the control group of patients, in one-month mortality rate. All the patients who were administered Itolizumab were weaned off oxygen by Day 30, and none needed ventilator support unlike the control group that did not get the drug. Some other inflammations commonly found in such patients were also suppressed, and these correlated well with clinical improvement in symptoms. Overall, the drug was found well-tolerated.

Express Explainedis now onTelegram. Clickhere to join our channel (@ieexplained)and stay updated with the latest

How large was the trial?

The trial had 20 participants given the drug along with supportive care and 10 others given only supportive care. All 20 patients on Itolizumab recovered while three of the other 10 patients died.

Public health experts and some doctors have used social media to question the sample size of the trial. When journalists raised this question at a virtual press conference, Kiran Mazumdar-Shaw, Executive Chairperson, Biocon, said Itolizumab has been approved in India and since the country is in a medical emergency, it was decided to go ahead with a clinical trial involving a cohort of 30 patients. She said the regulatory process was extremely robust and the scientific discussions on the trial was of a very high order.

The DCGI has also exempted the drug from phase III clinical trials and allowed phase IV trials (post-marketing surveillance). Itolizumab is not a new drug and was approved in India since 2013. We had done phase II and III trials, and got the approval. In the past seven years, its been used in psoriasis and we know how the mechanism works Biocon Biologics CMO Dr Athalye said. Company officials said they plan phase IV trials soon.

How much does it cost?

Each injection is presented as a 25mg/5ml solution, which costs Rs 7,950 per vial. Based on an average body weight of 60 kg, the therapy cost of a single dose comprising four vials is estimated at Rs 32,000 (MRP).

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Explained News, download Indian Express App.

The Indian Express (P) Ltd

See the original post here:

Explained: What is Itolizumab, newly cleared for Covid-19? - The Indian Express

Insights on the Global Chronic Plaque Psoriasis Therapeutics Market

PMR is one of the leading market research companies in India. Our team of research analysts have a deep understanding and knowledge related to the latest market research techniques and use their analytical skills to curate insightful and high-quality market reports. The presented data is collected from credible primary sources including marketing heads, sales managers, product managers, industry experts, and more.

As per the report, the global Chronic Plaque Psoriasis Therapeutics market reached a value of ~US$ XX in 2018 and is likely to surpass a market value of ~US$XX by the end of 2029. Further, the report reveals that the Chronic Plaque Psoriasis Therapeutics market is set to grow at a CAGR of ~XX% during the forecast period (2019-2029)

Request Sample Report @ https://www.persistencemarketresearch.co/samples/21442

Critical doubts related to the Chronic Plaque Psoriasis Therapeutics market addressed in the report:

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/21442

Segmentation of the Chronic Plaque Psoriasis Therapeutics market

The report bifurcates the Chronic Plaque Psoriasis Therapeutics market into different segments to provide a clear understanding of the various aspects of the market.

Regional Outlook

The regional outlook section of the report includes vital data such as the current trends, regulatory framework, The Chronic Plaque Psoriasis Therapeutics market study offers critical data including, the sales volume, sales growth, and pricing analysis of the different products in the Chronic Plaque Psoriasis Therapeutics market.

The key manufacturers engaged in developing the chronic plaque psoriasis therapeutics market include Abbvie, Inc., Novartis International AG, Pfizer, Inc., Merck & Co., Astelllas Pharma, Inc., GlaxoSmithKline Plc and others.

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/21442

Important insights present in the report:

Read more:

Chronic Plaque Psoriasis Therapeutics Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2017 2025 - 3rd Watch News

Ixekizumab, and other antibodies that target interleukin 17 monoclonal antibody (IL-17A), may reduce reactivations of tuberculosis in patients with latent tuberculosis infection (LTBI), according to a study research published in the Journal of the American Academy of Dermatology.

The findings were from a post hoc analysis of integrated safety data from 13 clinical trials of patients with psoriasis (n=5898) and 3 trials of patients with psoriatic arthritis (n=1118). The safety analyses reported treatment-emergent LTBI in patients who were treated with ixekizumab. Assessment of LTBI was made with the purified protein derivative skin test or QuantiFERON-TB Gold assay. Only patients who tested negative for LTBI either at screening or <3 months before baseline were included in the post hoc analysis.

It was noted that 1.7% (n=101) of patients with psoriasis developed treatment-emergent LTBI, and 65 of these patients discontinued ixekizumab. A total of 30 patients who remained in their trial initiated LTBI-specific therapy, whereas the other 6 patients who continued in their trial did not receive therapy.

It was found that 2.9% (n=32) of patients with psoriatic arthritis developed treatment-emergent LTBI, and 7 of the 12 patients who continued ixekizumab also received LTBI therapy. Only 5 patients were not treated with a LTBI-specific therapy. None of the 6 patients with treatment-emergent LTBI without LTBI-specific therapy during ixekizumab experienced reactivation of their disease.

Limitations of the analysis were the lack of a control group, the small number of events, and the short observation time.

The investigators wrote that additional real-world data are needed to address the clinical question on the potential long-term risk for reactivation of tuberculosis under anti-IL 17 therapy.

Disclosure: This clinical trial was supported by Eli Lilly and Company. Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors disclosures.

Reference

Mrowietz U, Riedl E, Winkler S, et al. No reactivation of tuberculosis in patients with latent tuberculosis infection receiving ixekizumab: A report from 16 clinical studies of patients with psoriasis or psoriatic arthritis [published online June 8, 2020]. J Am Acad Dermatol. doi: 10.1016/j.jaad.2020.06.012

Read more:

Ixekizumab May Prevent Reactivation of Tuberculosis in Patients With Latent Tuberculosis Infection - Dermatology Advisor

Most recent report on the global Psoriasis Drugs market

A recent market study reveals that the global Psoriasis Drugs market is likely to grow at a CAGR of ~XX% over the forecast period (2019-2029) largely driven by factors including, factor 1, factor 2, factor 3, and factor 4. The value of the global Psoriasis Drugs market is estimated to reach ~US$ XX Bn/Mn by the end of 2029 owing to consistent focus on research and development activities in the Psoriasis Drugs field.

Valuable Data included in the report:

Competitive Outlook

The presented business intelligence report includes a SWOT analysis for the leading market players along with vital information including, revenue analysis, market share, pricing strategy of each market players.

Some of the top tier players profiled in the report include:

Product adoption Analysis

A complete assessment of the market share, consumption patterns, and supply-demand ratio of each product is provided backed by insightful tables, figures, and graphs. The products covered in the report include:

The resourceful market study outlines the overall prospects of the Psoriasis Drugs market in the major geographies including region 1, region 2, region 3, and region 4. The most prominent market players, observable trends, opportunities, and challenges in each region is enclosed in the report.

Important Queries Addressed in the report:

Why Our Clients Trust Psoriasis Drugs Market Report?

With a systematic and methodic approach, our analysts collect data from credible primary and secondary sources. In addition, we offer the most efficient after sales services to our customers and address their problems without any delay.

See original here:

Psoriasis Drugs Market: Information, Figures and Analytical Insights 2019-2026 - Cole of Duty

On this page:Basics

Even though theres no cure for psoriatic arthritis (PsA), relief for your symptoms is likely just around the metaphorical cornerthe research into treating this inflammatory condition is moving that fast. Drug therapies for PsA are more targeted than ever, and lifestyle changes can make big improvements in your condition. Once youve been diagnosed with PsA, your primary care doctor will likely refer you to a rheumatologist to discuss your treatment options. Lets take a closer look at what those might entail.

Driven by an out-of-whack inflammatory response, psoriatic arthritis (PsA) is a chronic condition where your joints, ligaments, and tendons come under attack by your immune system, leading to pain, swelling, and stiffness that can do serious joint damage if left unchecked.

The disease is related to (but different from) the inflammatory skin condition known as psoriasisalthough about 30% of people with psoriasis will develop PsA at some point during their life, most commonly in their 30s and 40s.

While the jury is still out on the exact causes of PsA, experts believe it is a combination of genetics (about 40% of people with PsA have a family history of the disease), an overactive immune system, and things in the environment that you have been exposed to. It affects men and women in equal numbers and is most frequently diagnosed in people between the ages of 30 and 50.

When it comes to PsA treatment, one size doesnt fit all. Before deciding which approach is right for you, your doctor will do a physical exam and ask you questions to figure out how much (or little) PsA is getting in the way of your everyday activities.

Severe cases can cause long-term joint damage, while milder cases are more of an inconvenience, so its important to establish the degree to which PsA is affecting your personal situation first, before talking about treatment.

The goal of the treatment is simple: Reduce inflammation and the discomfort that you may be feeling so you can return to enjoying your life. The sooner treatment begins, the more successful it tends to be at easing symptoms and slowing down the disease. These are a few of the approaches you and your doc may discuss.

Uncontrolled inflammation is the underlying cause of most of the discomfort associated with psoriatic arthritis. How severe your inflammation is will often determine which treatment your doctor will chooseor at least, which therapy you start with. Fortunately, there are many effective medications available. You may find that you need to try several in combination to get the best results.

NSAIDs are usually the first step if your symptoms are very mild. They can help control the inflammation and joint pain. Some people feel relief almost immediately, while in others it may take several days. These drugs are not recommended for long-term use since they carry side effects like stomach irritation, heart problems, and kidney damage.

The most common NSAIDs include:

In addition, COX-2 inhibitors, a subclass of NSAIDs, may be prescribed. These have a lower risk of internal bleeding or stomach ulcersa common side effect of other NSAIDs that are used in large doses for a long time. Brand names include Bextra and Celebrex (celecoxib).

Shorthand for disease-modifying anti-rheumatic drugs, these treatments used to be the go-to regimen for treating PsA. They work by suppressing the bodys overactive immune system. Due to their immune-suppressing nature, they can come with side effects, like mouth sores, hair loss, stomach upset, infection, fatigue, or liver damage. If you are taking them, you should be closely monitored with regular (weekly to every few months) lab tests. Most DMARDs can all be taken orally, and methotrexate is also available as an injection.

The most common DMARDs include:

A sub-type of DMARDS, known as JAK inhibitors (short for Janus kinase) target a family of enzymes that trigger the immune system response. Drugs include:

Also known as biologic response modifiers, these medications hold much promise for the future of PsA treatments: Up to 60% of PsA patients achieved minimal disease activity after one year of treatment with biologics, according to a study in Arthritis Research & Therapy. These therapies have fewer side effects than DMARDs (although your risk of infection is greater).

Heres how they work: Biologics are protein-based drugs derived from living cells cultured in a laboratory. Their job is to control certain parts of the immune system by targeting the proteins that fuel inflammation and shutting them down. They are categorized based on the cells they target.

These are a few options your doctor may prescribe:

This class of drugs is now the first line of prescription treatment for people with PsA, according to guidelines issued in 2018 by the National Psoriasis Society and the American College of Rheumatology. These meds lower inflammation and slow the progression of PsA by targeting an inflammation-causing substance in the body called tumor necrosis factor (TNF).

Delivered by self-injection or IV, examples of TNF inhibitors include:

Another type of biologic treatment that has been found to be effective in treating PsA, these drugs act on a different pathway to control inflammation in your joints. Like TNF inhibitors, these meds are only available via infusion or injection.

Examples include:

A type of white blood cell related to your immune system, T-cells signal to your body that its under attack and time to launch an assault. Unfortunately, that assault, by way of inflammation, is mistakenly directed at your joints and tendons.

This class of medication inhibits T-cells from becoming activated, thereby reducing inflammation and subsequent joint damage. Its taken as an injection. Examples include Orencia (abatacept).

These drugs work by blocking an enzyme called phosphodiesterase 4 (PDE4), that is responsible for controlling inflammatory actions within the bodys cells. Currently there is only one PDE4 inhibitor approved for PsA. This drugOtezla (apremilast)can be taken orally.

Consider corticosteroids a short-term fix for symptoms while youre waiting for other longer-term medications to take effect. (They can also be prescribed for immediate relief during a flare.) Corticosteroids can be taken orally, intravenously, or injected right into the joint.

Long-term use should be avoided since it can lead to side effects like high blood sugar, high blood pressure, bone loss, and glaucoma. Patients coming off the drug should taper slowly over a few weeks. The most common corticosteroid is Deltasone (prednisone).

Surgery is not a standard treatment for those with PsA. However, if youve lived with psoriatic disease without a diagnosis or treatment, it is possible that it has caused permanent joint damage, in which case, your doctor may talk with you about arthoplastya procedure that replaces, reshapes, or reconstructs damaged joints.

Its a serious surgery, but also a common one: More than a million joint replacement procedures are performed each year, mostly of the hip or knee (your shoulders, elbows, and joints in the hands and feet can be replaced as well). There are pros and cons to going this routeand its usually reserved for the most severe cases of joint damage. Talk with your doctor if its something you think might help.

Along with medical procedures and drug intervention, there are a bunch of lifestyle changes you can make that will go a long way towards easing the painful symptoms of psoriatic arthritis. This list here can help you get started.

Drink less alcohol. Heavy drinking can lower your response to PsA treatment. Unchecked alcohol consumption will also fill you up with a glut of empty calories, leading to unwanted pounds that place extra stress on your joints.

Exercise more. Exercising regularly can help psoriatic arthritis in several ways: It reduces joint pain by keeping muscles strong and supporting the joints; it helps you lose or maintain a healthy weight so there is less load on your joints and ligaments; and it can improve your mood and reduce stress. If you are having a flare, you will need to listen to your body. Dont be afraid to back off or take more frequent breaks as you work out. After all, any amount of exercise is better than none.

Explore hot/cold therapy. A warm shower or bath can work wonders on stiff, painful joints. Heat reduces muscle tension and stimulates blood circulation, which may help joints feel better. (Heat can also irritate your skin and cause a flare, so its a tricky balance.) A cold compress, on the other hand, may help reduce inflammation, swelling, and soreness during a flare or after more than your usual amount of activity.

Manage stress. The bottom line: Stress can trigger a flare. Try exercise, meditation, yoga, or deep breathing if tension is making your symptoms worse. And if anxiety or depression is interfering with your life or ability to function, dont hesitate to seek help.

Quit smoking. Smoking can increase your risk of psoriasis and may make symptoms significantly worse. It can also prevent your treatment for working effectively. While the exact causes are unknown, one theory is that cigarettes contain thousands of different ingredients that may promote inflammation.

Sleep better. Sleep is incredibly important for everyone, but if you have psoriatic arthritis, it's especially key because a major part of joint and tissue repair happens when you are asleep. Unfortunately, pain related to PsA can interrupt sleep and so can certain medications like steroids. If youre struggling to get a steady seven to nine hours a night, talk with your doctor about possible solutions.

Use topical creams. Applying creams or lotions containing capsaicin (an extract from chili peppers) may temporarily soothe minor joint pain. Ditto for those with camphor, menthol, or turpentine oil.

Watch your diet. While a direct correlation between diet and psoriatic arthritis has yet to be proven, avoiding foods known to trigger inflammation in the body is sort of a no-brainer. Desserts, soda, white bread, and other foods that are high on the glycemic index tend to cause a temporary spike in blood sugar, which promotes inflammation.

Wear supportive shoes. Sorry to say it, but your days of flip flops and cheap shoes may be behind you. Shoes that provide stability and cushioning can help your feet feel better and provide a solid foundation for your knees, hips, back, and neck. Do what you need to stay comfortable and supported. You may find that changing shoes several times a day is preferable.

There isnt a ton of research to say conclusively one way or the other, but theres little downside to adding these two natural supplements into your diet.

A few studies suggest that supplementation of about 3.3 grams daily of fish oil, which contains high amounts of omega-3 fatty acids, may help reduce pain and stiffness. Salmon, walnuts, and flax seed are also sources of omega-3s. Dont overdo though: High doses of omega-3 supplements can cause nausea, cramps, and increase bleeding risks in people who take blood thinners. As always, talk with your doc first.

Turmeric has been used as a spice for centuries. Several small studies show that turmeric and its major ingredient (curcumin) may help treat arthritis symptoms just as effectively as pain medicines like ibuprofen. You can find it as a supplement and can also use it to cook with or add to your tea or smoothies.

All of these options may sound overwhelming to you. Its hard to know where to startwhich is why the best thing you can do is make a list of questions and schedule an appointment with your doctor. As you talk, keep your mind focused on the fact that with the right treatment, the majority of those living with PsA get their symptoms under control and achieve remission. In fact, with certain treatment programs, more than half of patients see symptoms virtually disappear in a years time. Pretty good!

Of course, the trick is finding the right combination of meds, and that can be a bit of trial and error. Dont give up. It can take months, but once you settle of a combo that works for you, youll be well on your way to getting your life back the way you want it. Most likely, youll need to stay on the meds indefinitely, since even though the disease may quiet down, its there, waiting to strike if given half a chance. Still, thats a small price to pay for pain-free living.

Thats a doctor who is specially trained in diagnosing and treating PsA and other rheumatic diseases (musculoskeletal diseases and systemic autoimmune disorders). To see one, you may need a referral, either from your primary care doc or another physician.

Nope, sorry. PsA is not yet curable. If you are taking medication and your symptoms improve, do not stop taking your medications without talking to your doctor. Discontinuing your medications could cause your symptoms to return and even get worse.

PsA treatment varies as does the time it takes to see results. For example, you may get immediate relief from a cortisone injection, but it may take months for a biologic medication to work effectively.

Actually, yes. Kids can get this disease, and when they do, its referred to as pediatric psoriatic arthritis. If your child shows symptoms, seek treatment as soon as possible. The approach will be similar for that of adults with PsA.

Read the original here:

What Are Your Psoriatic Arthritis Treatment Options? - HealthCentral.com

There are an estimated 8 million people in the United States living with psoriasis, a chronic condition that results in painful skin lesionsraised, scaly patches called plaques, boils (known as pustules), or areas of redness and swelling. For affected folks, the threat of a flare-up is always lurking, constantly shaking their confidence in social situations, at school, or at work. That's tough enough to deal with when you can hide within the walls of your cubicle. But what do you do when your "office" is the squared circle?

Growing up in Rochester, New York, Dewey Murray had a singular career goal: wrestle in the WWE. A psoriasis diagnosis at the age of 13 did nothing to derail that dream. At 15, he graduated from a local wrestling academy. By 18, he was building his name on the indie wrestling circuit.

Though the storylines and match results were choreographed, the stunts still carried massive risks. For Murray, the opportunity to conquer the fear of those high-flying physical feats was one of the best features of his job. He could get past putting himself at great risk of injury (or worse). Hell, he embraced it. But when it came to the fear of an in-ring skin flare-up that would bring judgementfrom his fellow wrestlers, the thousands in attendance, and millions watching at homethat anxiety was almost too much.

This is not your average day job. Youre in physical contact with your coworkers.

At just 23 years old and having booked his first gig with the WWE, what should have been a dream come true was rapidly devolving into a nightmare scenario. Murray's big-league debut would require him to have his head shaved in an arena filled with 14,000 screaming wrestling fans, for a segment broadcast live on TV. This should have been his career-launching moment, but all Murray could think about was how his psoriasis might blow the whole thing.

How bad were his plaques? Would the camera be close enough to show them? What would his head look like shaved? What if he bled? What about the guys wielding the electric razor? They were wrestlers, not professional barbers. As the unanswerable questions mounted and Murray imagined the many ways things could go wrong, he was filled with dread.

So much goes through your head because its on live TV and theres no redo, no Hey I have this spot showing, lets hit makeup and run back out and redo it, says Murray, now 32. Im not one to be honest about my anxiety, but that was by far the most stressful day with having psoriasis.

Today, Murray looks back on that day as one of his happiest in wrestling. The spot went well, the few patches he had on his scalp weren't visible on TV, and afterward when he visited a stylist, she didn't mention anything while cutting his hair.

Still, Murray's psoriasis affected his confidence on the job. Other wrestlers knew about Murray's condition; some refused to get in the ring with him, even though it isnt contagious. Mostly, he worried about the crowd finding out. Its one thing when you can go to work every day and dress in a way that hides your skin condition, but as a wrestler you arent able to do that, he says.

About a year after the head-shaving stunt, to control what the crowd saw, Murray developed a trucker persona that allowed him to dress in layers from head to toe, so fans would be none the wiser. He wore jeans with a big flannel shirt and wrapped bandanas around his elbows to hide flare-ups. When the bandanas proved popular with fans, Murray sold them at merch tables. Theres always a positive with the negative, he likes to say.

Murray's trucker persona did the trick. Since 2011, he's had steady work for the likes of Ring of Honor, Total Nonstop Action, and more appearances with WWE; in 2015, he even cracked the world top-500 rankings in Pro Wrestling Illustrated. But while his career continued, keeping his skin condition under wraps took a psychological toll.

At one particular match, Murrays opponentsomeone he had idolized over the yearswas late to arrive, so they didnt have a chance to meet beforehand. After the match was over, Murray sought him out to formally introduce himself. As he extended his hand, the wrestler told him, Im not going to shake your herpes hand.

This is not your average day jobHey Susan, hows it going?this is wrestling. Youre in physical contact with your coworkers, Murray says. When that happened, I didnt know whether to hit him or cry.

This content is imported from Twitter. You may be able to find the same content in another format, or you may be able to find more information, at their web site.

Finally, in 2017, after trying virtually every possible treatmentphoto light-boxes that left burn marks, coal tar shampoo and body wash, sea salt soaks, a hundred creams, lotions, oils, pills, and injectablesMurray, with the help of his dermatologist, found a biologic that worked for him. He hasnt had a flare-up since.

Today, Murray is still in the ring, touring the US and Canada on the indie wrestling circuit as an independent contractor, and occasionally appearing on TV, free of anxiety. Before, I was scared to do certain stuff [in the ring] because I was afraid of hitting the wrong way and bleeding everywhere because of the plaques on my body, he says. [Now,] its amazing to go out there and do crazy stuff and know that if a bandana comes off, I dont have to tie it back on. Professionally, I dont have a care in the world.

This content is created and maintained by a third party, and imported onto this page to help users provide their email addresses. You may be able to find more information about this and similar content at piano.io

This commenting section is created and maintained by a third party, and imported onto this page. You may be able to find more information on their web site.

More here:

This Pro Wrestler Overcame His Skin Condition and Got His Swagger Back - Men's Health